series-a
Stage
1
Investors
About
BiomeBank develops microbiome therapeutics designed to restore the natural diversity of the human gut ecosystem, producing next-generation co-cultured microbial products to treat diseases such as ulcerative colitis and recurrent Clostridioides difficile infection.
Explore BiomeBank's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.